Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).
PMID: 34795836
2021
The Pan African medical journal
Result: Besides DRMs assessed by PANDAA (K65R, M184V, K103N, Y181C and G190A), additional major DRMs to NRTI (L74I, D67N, K70E and K219R
Result: The mutation L74I is selected primarily by didanosine and abacavir (ABC) and occasionally by TDF; K219N/R are accessory thymidine analog mutations (TAMs) that usually occur in combination with multiple other TAMs; D67N is a non-polymorphic TAM associated with low-level resistance to zidovudine and stavudine and K70E cause low-level resistance to TDF and ABC.
Characterizing HIV-1 Genetic Subtypes and Drug Resistance Mutations among Children, Adolescents and Pregnant Women in Sierra Leone.
Abstract: Among pregnant women, the most frequent RAMs were K103N (20.6%, n = 7/34), M184V (11.8%, n = 4/34), Y181C/V/I (5.9%, n = 2/34), P225H (8.8%, n = 3/34), and K219N/E/Q/R (5.9%, n = 2/34).
Result: The most prevalent RT RAMs in pregnant women were as follows: K103N (20.6%, n = 7/34), M184V (11.8%, n = 4/34), Y181C/V/I (5.9%, n = 2/34), P225H (8.8%, n = 3/34), K219N/E/Q/R (5.9%, n = 2/34), and K238T (5.9%, n = 2/34) (Figure 1a,b).
Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.
Method: Thymidine-analog mutations were defined as the NRTI-SDRMs M41L, D67N/G/E, K70R, L210W, T215Y/F/S/C/D/E/I/V, and K219Q/E/N/R.
Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Abstract: Using the 2% detection threshold, individual DRMs with the highest prevalence were: PI M46IL (5.5%), RT Result: The most common NRTI DRMs were T215 revertants (2.5%), M41L (2.2%), and K219QENR (1.7%).
Result: occurring in > 80% of the viral population), whereas a wider range of variant frequency was observed for K219QENR.
Discussion: The most commonly detected NRTI DRMs, K219QENR and M184VI, occurred predominately as minor variants while the majority of patients with T215 revertants had the mutation in > 80% of the quasispecies.
Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon.
Abstract: Fifteen (15) PDR mutations were found among four patients the urban settings [6 resistance mutations to NRTIs:[M41L (2), E44D (1), K65R (1), K70E (1), M184V/I (2), K219R (1)] and 6 resistance mutations to NNRTIs: K103N (1), E138A/G (2), V179E (1), M230L (1), K238T (1), P225H (1)] against two (02) mutations found in two patients in the rural setting[2 resistant mutations to NNRTIs: E138A (1) and
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Result: Other NRTI resistance mutations were K65R and K219R.
Table: K219R
The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017.
Abstract: 48 DRMs were identified from 43 samples, indicating a drug resistance prevalence of 12.1% (43/356), which include seven protease inhibitors (PIs) accessory DRMs (Q58E, L23I and I84M), two PIs major DRMs (M46I, M46L), seven nucleoside RT inhibitors DRMs (D67N, K70Q, K219R and M184L), and 32 non-nucleoside RT inhibitors DRMs (K103N, V179E, K238N, V179D, PMID: 32986709
2020
PloS one
Table: K219R
Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.
HIV mutation literature information.
PMID: 
2021
The Pan African medical journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT